Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>The first half of 2026 for Genmab A/S showed robust growth and operational progress driven by both commercial execution and pipeline development.</li>
<li>Revenues increased by 25% year-over-year, supported by strong performances from key products including EPKINLY and DARZALEX.</li>
<li>EPKINLY’s net sales rose 48%, reflecting accelerated patient starts and site activations in the U.S. and a broadening global presence through partner AbbVie, with recent approvals in Europe, Japan, and China.</li>
</ul>


The first half of 2026 for Genmab A/S showed robust growth and operational progress driven by both commercial execution and pipeline development.
Revenues increased by 25% year-over-year, supported by strong performances from key products including EPKINLY and DARZALEX.
EPKINLY’s net sales rose 48%, reflecting accelerated patient starts and site activations in the U.S. and a broadening global presence through partner AbbVie, with recent approvals in Europe, Japan, and China.


Genmab Unlocks A New EPKINLY Opportunity — Europe Expands Into Second-Line Follicular Lymphoma!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Genmab is a leader in antibody therapeutics, with a business model centered on its proprietary technology platforms (e.g., DuoBody®, HexaBody®) to develop a pipeline of innovative cancer treatments.</li>
  <li>The company's financial strength is historically rooted in high-margin royalties from its blockbuster drug DARZALEX (daratumumab), partnered with Johnson &amp; Johnson. However, it is strategically shifting towards co-owned and wholly-owned assets to diversify and secure long-term growth.</li>
  <li>Future growth hinges on the successful commercialization of its late-stage pipeline, including EPKINLY® (epcoritamab) and newly acquired assets, to mitigate the risk of revenue concentration and the eventual patent expiration of DARZALEX.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Genmab is a leader in antibody therapeutics, with a business model centered on its proprietary technology platforms (e.g., DuoBody®, HexaBody®) to develop a pipeline of innovative cancer treatments.
  The company's financial strength is historically rooted in high-margin royalties from its blockbuster drug DARZALEX (daratumumab), partnered with Johnson &amp; Johnson. However, it is strategically shifting towards co-owned and wholly-owned assets to diversify and secure long-term growth.
  Future growth hinges on the successful commercialization of its late-stage pipeline, including EPKINLY® (epcoritamab) and newly acquired assets, to mitigate the risk of revenue concentration and the eventual patent expiration of DARZALEX.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

<ul>
<li>Genmab A/S is making headlines again, this time by sealing the U.S. leveraged finance market’s biggest M&amp;A funding since April with a $4.5 billion raise through junk bonds and a leveraged loan.</li>
<li>The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025.</li>
<li>This bold move comes amid Genmab’s rapidly scaling commercial operations and late-stage pipeline expansion, headlined by drugs like EPKINLY and Rina-S.</li>
</ul>


Genmab A/S is making headlines again, this time by sealing the U.S. leveraged finance market’s biggest M&amp;A funding since April with a $4.5 billion raise through junk bonds and a leveraged loan.
The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29, 2025.
This bold move comes amid Genmab’s rapidly scaling commercial operations and late-stage pipeline expansion, headlined by drugs like EPKINLY and Rina-S.


Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside!

Genmab’s $8 Billion Bet: What The Merus Deal Could Unlock!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We had been near-term bullish on the S&amp;P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral</li>
<li>The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here</li>
<li>Still, our intermediate-term outlook remains bullish (as of 5/14/25 report), and we'll maintain our bullish intermediate-term view as long as market dynamics remain constructive and the SPX is above 6200</li>
</ul>


We had been near-term bullish on the S&amp;P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral
The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here
Still, our intermediate-term outlook remains bullish (as of 5/14/25 report), and we'll maintain our bullish intermediate-term view as long as market dynamics remain constructive and the SPX is above 6200


Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

Denmark

Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Genmab A/S (GMAB US)

Genmab Unlocks A New EPKINLY Opportunity — Europe Expands Into Second-Line Follicular Lymphoma!

The first half of 2026 for Genmab A/S showed robust growth and operational progress driven by both commercial execution and pipeline development.

Baptista Research

Primer: Genmab A/S (GMAB US) - May 2026

Genmab is a leader in antibody therapeutics, with a business model centered on its proprietary technology platforms (e.g., DuoBody®, HexaBody®)...

αSK Primers

Genmab: How Its Combined Pipeline, Royalties & M&A Strategy Could Potentially Unlock A SOLID Upside!

The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29,...

Baptista Research

Genmab’s $8 Billion Bet: What The Merus Deal Could Unlock!

The Danish biotech giant is gearing up to acquire Merus N.V., a smaller Dutch peer, in a proposed $8 billion transaction announced on September 29,...

Baptista Research

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight

Coasting as We Stalk for Buying Opportunity; Downgrading Near-Term Outlook to Neutral, But Still Bullish Intermediate-Term $SPX $QQQ; Downgrading...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)